Literature DB >> 10647156

Effects of EPC-K1 on lipid peroxidation in experimental spinal cord injury.

T Fujimoto1, T Nakamura, T Ikeda, Y Taoka, K Takagi.   

Abstract

STUDY
DESIGN: A study in which levels of lipid peroxidation were measured, the thiobarbituric acid-reactive substances were estimated in an experimental rat model, and the recovery was assessed.
OBJECTIVE: To ascertain the occurrence of thiobarbituric acid-reactive substances in the damaged spinal cord, and to investigate the effectiveness of a hydroxyl radical scavenger EPC-K1, a phosphate diester linkage of vitamins E and C, in attenuating the severity of spinal cord injury. SUMMARY OF BACKGROUND DATA: Lipid peroxidation has been reported to play an important role in spinal cord injury. There is no report on the use of EPC-K1 to attenuate the severity of spinal cord injury in either animal or human studies.
METHODS: Spinal cord injury was induced by placing a 25-g weight on T12, and the animals were divided into six groups. Group 1 (sham) received only laminectomy. Group 2 (control) received spinal cord injury. Group 3 received EPC-K1 5 minutes before injury. Group 4 received it 5 minutes after injury. Group 5 received it 3 hours after injury. Group 6 received it five times, respectively: at 5 minutes, then 1, 2, 3, and 4 hours after injury. The levels of thiobarbituric acid-reactive substances were measured in the spinal cord, and the recovery was assessed.
RESULTS: The thiobarbituric acid-reactive substances content increased after injury, with two peaks, at 1 and 4 hours. Concentration at the 4-hour peak was lower in nitrogen mustard-induced leukocytopenia rats than in the control rats. The EPC-K1 injection reduced thiobarbituric acid-reactive substances content at 1 and 4 hours after injury in Group 3 (respectively, 34.3% and 42.7% vs. control) and only that at 4 hours in Group 6 (24.9% vs. control). Motor function recovery and histologic findings were better in these two groups than in Group 2.
CONCLUSION: Repeated injection of EPC-K1 attenuated the severity of spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647156     DOI: 10.1097/00007632-200001010-00006

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  7 in total

1.  Different preoperative approaches for acute lumber spinal fractures.

Authors:  Lu-Feng Tian; Yan-Sheng Yuan; En-Hui Li; Lei Wang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Molecular targets in spinal cord injury.

Authors:  Stefan Klussmann; Ana Martin-Villalba
Journal:  J Mol Med (Berl)       Date:  2005-08-02       Impact factor: 4.599

3.  Anti-apoptotic and anti-oxidative roles of quercetin after traumatic brain injury.

Authors:  Tao Yang; Bin Kong; Jian-Wen Gu; Yong-Qin Kuang; Lin Cheng; Wen-Tao Yang; Xun Xia; Hai-Feng Shu
Journal:  Cell Mol Neurobiol       Date:  2014-05-21       Impact factor: 5.046

Review 4.  Current and future medical therapeutic strategies for the functional repair of spinal cord injury.

Authors:  Tevfik Yılmaz; Erkan Kaptanoğlu
Journal:  World J Orthop       Date:  2015-01-18

5.  The antioxidant effect of beta-Glucan on oxidative stress status in experimental spinal cord injury in rats.

Authors:  Hakan Kayali; M Fatih Ozdag; Serdar Kahraman; Ahmet Aydin; Engin Gonul; Ahmet Sayal; Zeki Odabasi; Erdener Timurkaynak
Journal:  Neurosurg Rev       Date:  2005-04-30       Impact factor: 3.042

6.  Effects of methylprednisolone and hyperbaric oxygen on oxidative status after experimental spinal cord injury: a comparative study in rats.

Authors:  Serdar Kahraman; Bülent Düz; Hakan Kayali; Ahmet Korkmaz; Sükrü Oter; Ahmet Aydin; Ahmet Sayal
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

7.  Does hypothermic treatment provide an advantage after spinal cord injury until surgery? An experimental study.

Authors:  Bulent Duz; Metin Kaplan; Serkan Bilgic; Ahmet Korkmaz; Serdar Kahraman
Journal:  Neurochem Res       Date:  2008-07-17       Impact factor: 3.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.